Wellbeing and Resilience Among 1-3 Years Old Children of Mothers with Complex Mental Health Problems: a Pragmatic Clinical Trial of Online VIPP-SD Vs. Care As Usual (WellCom)

January 25, 2025 updated by: Kirstine Agnete Davidsen, University of Southern Denmark

Wellbeing and Resilience Among 1-3 Years Old Children of Mothers with Complex Mental Health Problems: a Pragmatic Clinical Trial

Children of parents with severe mental disorders have an increased risk of mental disorders themselves, with more than half of this population diagnosed with a mental health condition during their life time. Already during early childhood, the risk of a mental health diagnosis is elevated by a factor 2-5, compared to children of parents without severe mental disorders. This highlights the need for preventive interventions.

Mental health during early childhood is inextricably linked with early parent-child interaction. Sensitive parenting plays a crucial role in the socio-emotional development of the child, and severe parental mental disorders may affect the quality of parent-child interaction.

Therefore, we will test the effect of an intervention promoting sensitive parenting on mental health outcomes of 1-3 years old children of parents with severe mental disorders. The intervention will be tested in a randomized clinical trial comparing the intervention "Video-feedback Intervention to Promote Positive Parenting and Sensitive Discipline" (VIPP-SD) delivered online to Care As Usual. Our hypothesis is, that children in the Intervention Group will display lower levels of behavioral problems and increased attachment security compared to children in the Care As Usual Group.

The study will be conducted in the department of Child and Adolescent Psychiatry, Mental Health Services in the Region of Southern Denmark. Participants are mothers with a diagnosis of schizophrenia, bipolar disorder, emotionally unstable personality disorder or moderate to severe depression living in the Region of Southern Denmark with their 1-3 years old child, and the father/cohabitating partner. Participants will be recruited via psychiatric outpatient clinics in the region or on the basis of information from health registers.

The primary outcome of the study is child behavioral problems. Secondary child outcomes are attachment security and mental health. Parental outcomes are parental stress and quality of life. Child cognition, parental psychiatric symptoms, childhood trauma, sensitivity, parental reflective functioning and service use data are also assessed in the study. Data are collected at baseline as well as 5 and 11 months after randomization. All participants will have the opportunity to receive feedback on their child's cognitive functioning and mental health status at baseline and at the end of the study.

After baseline assessments, participants will be randomized to either intervention or the control group.

The intervention, VIPP-SD, is delivered online apart from the first session, which is conducted as a home visit. VIPP-SD is based on attachment and social learning theory. It is manualized and consists of 12 individual sessions alternating between video-recording of mother and child in pre-defined everyday situations and review/discussion of the video recordings with the mother/parents. Focus of the intervention is the childs signals and needs, and how to promote healthy socio-emotional development of the child. VIPP-SD will be carried out by health care professionals trained and certified in VIPP-SD.

Participants who are randomized to the control condition, Care As Usual, will continue as they did before enrollment to the study. Care As Usual is defined as any kind of help and support related to the social-emotional development and mental wellbeing of the child in the municipality or mental health services.

Study Overview

Study Type

Interventional

Enrollment (Estimated)

120

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

    • Region of Southern Denmark
      • Odense C, Region of Southern Denmark, Denmark, 5000
        • Recruiting
        • Research Unit of Child and Adolescent Psychiatry, Mental Health Services in the Region of Southern Denmark
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • child age 1 year, 0 months until 3 years, 0 months
  • living with their mother in the Region of Southern Denmark
  • mother has a mental disorder (Schizophrenia ICD-10: F20-29, Bipolar disorder ICD-10: F30-31, Moderate to severe depression ICD-10: F32-33 or Emotionally unstable personality disorder F60.3) verified in the Danish National Hospital Register-Psyk/the Danish Psychiatric Central Research Register or by a clinician at the mental health services via the patient record
  • mother has had at least one in- or outpatient contact with mental health services within 12 months before birth of the child or during the child's lifetime verified in the Danish National Hospital Register or by a clinician at the mental health services via the patient record

Exclusion Criteria:

  • current in-patient status of the mother
  • current substance or alcohol abuse of the mother
  • mother has insufficient knowledge of Danish (interpreter required)
  • repeated intrauterine exposure to euphoriants or large amounts of alcohol (≥5 units per time or ≥7units per week) of the child
  • known syndrome or autism spectrum disorder of the child
  • mother or child has sensory impairment
  • sibling participating in study
  • family participating in another closely related research trial receiving an individualized video-feedback intervention
  • participating in active court proceedings

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Intervention (VIPP-SD)
Video-feedback Intervention to promote Positive Parenting and Sensitive Discipline (VIPP-SD) delivered online
The Video-feedback Intervention to promote Positive Parenting and Sensitive Discipline is delivered online in this study. VIPP-SD is a manualized parenting intervention. The online version consists of 12 individual sessions, where the first and hereafter every second session consists of video recordings of mother and child in pre-defined everyday situations. The recordings are reviewed and discussed with the mother/parents during subsequent video-feedback sessions, where positive sequences in the interaction are pointed out by the intervener and form the basis of a discussion of pre-defined themes regarding child signals, attachment, child development, limit setting and sensitive parenting. The 12 sessions are conducted within five months from randomization with weekly or bi-weekly intervals.
Other: Care As Usual
Care As Usual is defined as any kind of help and support the parents may receive related to the socio-emotional development and mental wellbeing of their child in the municipality or the mental health services.
Care As Usual is defined as any kind of help and support the parents may receive related to the socio-emotional development and mental wellbeing of their child in the municipality or the mental health services.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Preschool Parental Account of Children's symptoms (P-PACS)
Time Frame: The P-PACS will be administered at baseline (T0), 5 months (T1) and 11 months (T2) after randomization.
The P-PACS is a semistructured researcher-led interview administered to the mother, assessing level of child behavioral problems. Change in level of child behavioral problems is the primary outcome of the study.
The P-PACS will be administered at baseline (T0), 5 months (T1) and 11 months (T2) after randomization.

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Child Behavior Check List/1 ½-5 (CBCL/1 ½-5)
Time Frame: CBCL/1 ½-5 will be administered at baseline (T0), 5 months (T1) and 11 months (T2) after randomization.
The Danish version of the CBCL/1 ½-5 will be completed by both (cohabitating) parents. Change in Total problems score, and Internalizing and Externalizing subscale scores is used as a secondary outcome measure.
CBCL/1 ½-5 will be administered at baseline (T0), 5 months (T1) and 11 months (T2) after randomization.
Caregiver-Teacher Report Form (C-TRF)
Time Frame: C-TRF will be administered at baseline (T0), 5 months (T1) and 11 months (T2) after randomization.
The Danish version of the C-TRF will be completed by the child's day care teacher. Change in Total problems score, and Internalizing and Externalizing subscale scores is used as a secondary outcome measure.
C-TRF will be administered at baseline (T0), 5 months (T1) and 11 months (T2) after randomization.
Baby-DIPS
Time Frame: Baby-DIPS will be administered at baseline (T0), 5 months (T1) and 11 months (T2) after randomization.
The Baby-DIPS is a structured interview designed for the diagnosis of former and current regulatory problems (excessive crying, feeding or sleeping disorder). It is conducted with the mother. Change in regulatory problems will be used as a secondary outcome.
Baby-DIPS will be administered at baseline (T0), 5 months (T1) and 11 months (T2) after randomization.
the Brief Attachment Scale-16 (BAS-16)
Time Frame: The BAS-16 will be administered at baseline (T0) and 11 months (T2) after randomization.
BAS-16 is used for evaluating child attachment security in relation to both mother and (cohabitating) father. The BAS-16 is based on two scales, the "happy and harmonious interactions" and "proximity and physical-contact seeking". Change in mean score will be used as outcome.
The BAS-16 will be administered at baseline (T0) and 11 months (T2) after randomization.
Parental Stress Scale (PSS)
Time Frame: The Parental Stress Scale will be administered at baseline (T0), 5 months (T1) and 11 months (T2) after randomization.

The questionnaire Parental Stress Scale will be completed by both (cohabitating) parents. A total score and two subscale scores (Parental Stress and Parental Satisfaction) will be calculated.

Change in mean scores will be used as outcome.

The Parental Stress Scale will be administered at baseline (T0), 5 months (T1) and 11 months (T2) after randomization.
Parental Sensitivity
Time Frame: Sensitivity will be assessed at T0 and T1.
Parental sensitivity wil be assessed with the Coding of Interactive behavior on the basis of video-recordings of child in interaction with mother and father/cohabitating partner during a structured interaction containing a difficult task. The sensitivity socre is a composite score based on predefined parental subscales and ranges between one and five, with high scores indicating a high degree of sensitivity.
Sensitivity will be assessed at T0 and T1.
Parental Reflective Functioning Questionnaire (PRFQ)
Time Frame: The PRFQ will be completed by both (cohabitating) parents at baseline (T0), 5 months (T1) and 11 months (T2) after randomization.
The PRFQ is a questionnaire assessing self-reported parental reflective functioning. The items are divided into three categories: Prementalizing modes, Certainty about mental states and Interest and curiousity about mental states.
The PRFQ will be completed by both (cohabitating) parents at baseline (T0), 5 months (T1) and 11 months (T2) after randomization.
EQ-5D-5L
Time Frame: EQ-5D-5L will be administered at baseline (T0), 5 months (T1) and 11 months (T2) after randomization.
Quality of life is assessed with the Danish version of the EQ-5D-5L, a self-report measure assessing the impact of health on an individual's everyday life. EQ-5D-5L is completed by both (cohabitating) parents. Change in mean score will be used as secondary outcome measure.
EQ-5D-5L will be administered at baseline (T0), 5 months (T1) and 11 months (T2) after randomization.
Symptom Checklist-90-revised (SCL-90-R)
Time Frame: The SCL-90-R is completed at baseline (T0), 5 months (T1) and 11 months (T2) after randomization.
The SCL-90-R is a self-report questionnaire, which will be used to evaluate parental psychopathology. It is completed by both (cohabitating) parents.
The SCL-90-R is completed at baseline (T0), 5 months (T1) and 11 months (T2) after randomization.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Davi, Mental Health Services in the Region of Southern Denmark

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

February 1, 2025

Primary Completion (Estimated)

January 31, 2028

Study Completion (Estimated)

January 31, 2028

Study Registration Dates

First Submitted

January 20, 2025

First Submitted That Met QC Criteria

January 25, 2025

First Posted (Actual)

March 25, 2025

Study Record Updates

Last Update Posted (Actual)

March 25, 2025

Last Update Submitted That Met QC Criteria

January 25, 2025

Last Verified

January 1, 2025

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • S-20240007
  • 158789 (Other Grant/Funding Number: TrygFonden)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Behavioral Symptoms

Clinical Trials on Online VIPP-SD

Subscribe